Biossil

About Biossil

Biossil Inc. is a Toronto-based drug discovery company founded in 2023 by the serial entrepreneurial duo of Anthony Mouchantaf, who serves as CEO, and Alexander Mosa, who acts as Chair and Chief Scientific Officer. This venture marks their second collaboration, following the successful build and sale of a mobile health and genetic testing business to a public company. Their history of working together provides a foundation of experience for their current endeavor in the competitive biopharmaceutical landscape.

The company operates at the intersection of artificial intelligence and medicine, focusing on developing targeted therapies for specific, biologically-defined patient subpopulations. This approach addresses a critical challenge in traditional drug discovery: the frequent failure of clinical trials due to population variability, where a drug's efficacy can be obscured. Biossil's core strategy is to identify and rescue safe but failed therapeutic compounds, advancing them to market with greater speed and capital efficiency. The company's business model appears to be centered on in-licensing or acquiring drug candidates and then leveraging its AI platform to identify the patient groups most likely to respond, thereby de-risking and accelerating the development process. A recent example is the July 2025 out-licensing agreement with Applied Therapeutics for AT-001, a treatment for Diabetic Cardiomyopathy. Biossil gained exclusive worldwide rights to develop and commercialize the drug, providing Applied Therapeutics with an upfront payment and the potential for future royalties and milestone payments.

At the heart of Biossil's operation is its proprietary platform, "Excavate". This advanced multimodal AI system synthesizes over a trillion data points, combining multi-omics pipelines with large-scale Electronic Medical Record (EMR) data. Its function is to translate disease sub-phenotypes into distinct molecular endotypes, which are defined by disease modules at the interactome scale. This allows the company to uncover the molecular underpinnings of disease variability and pinpoint therapies for the right patient cohorts. The company has secured an undisclosed amount of seed funding in a round led by Staircase Ventures in February 2024, with Panache Ventures, Quiet Capital, and Golden Ventures also participating as investors.